{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:05:33Z","timestamp":1774526733919,"version":"3.50.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374133, 82074109, 81873078 and 81374051"],"award-info":[{"award-number":["82374133, 82074109, 81873078 and 81374051"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04705-2","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:03:51Z","timestamp":1771484631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Yike","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adili","family":"Tuersun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shah Syed Alfakhar","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyuan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linglu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"4705_CR1","doi-asserted-by":"crossref","unstructured":"2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S27-s49.","DOI":"10.2337\/dc25-S002"},{"issue":"14","key":"4705_CR2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jama.2023.4063","volume":"329","author":"JB Echouffo-Tcheugui","year":"2023","unstructured":"Echouffo-Tcheugui JB, Perreault L, Ji L, et al. Diagnosis and management of prediabetes: a review. JAMA. 2023;329(14):1206\u201316.","journal-title":"JAMA"},{"key":"4705_CR3","volume-title":"IDF diabetes atlas","author":"Federation ID","year":"2025","unstructured":"Federation ID. IDF diabetes atlas. 11th edn. International Diabetes Federation; 2025.","edition":"11th edn"},{"issue":"9833","key":"4705_CR4","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/S0140-6736(12)60283-9","volume":"379","author":"AG Tab\u00e1k","year":"2012","unstructured":"Tab\u00e1k AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279\u201390.","journal-title":"Lancet"},{"key":"4705_CR5","doi-asserted-by":"crossref","unstructured":"3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S50-s8.","DOI":"10.2337\/dc25-S003"},{"issue":"8","key":"4705_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S2213-8587(23)00132-8","volume":"11","author":"L Zhang","year":"2023","unstructured":"Zhang L, Zhang Y, Shen S, et al. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2023;11(8):567\u201377.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4705_CR7","doi-asserted-by":"crossref","unstructured":"Madsen KS, Chi Y, Metzendorf MI, et al. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019;12(12):Cd008558.","DOI":"10.1002\/14651858.CD008558.pub2"},{"key":"4705_CR8","doi-asserted-by":"crossref","unstructured":"Moelands SV, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018;12(12):Cd005061.","DOI":"10.1002\/14651858.CD005061.pub3"},{"key":"4705_CR9","doi-asserted-by":"crossref","unstructured":"Ipsen E, Madsen KS, Chi Y, et al. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020;11(11):Cd013516.","DOI":"10.1002\/14651858.CD013516.pub2"},{"key":"4705_CR10","doi-asserted-by":"crossref","unstructured":"Hemmingsen B, Sonne DP, Metzendorf MI, et al. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;5(5):Cd012204.","DOI":"10.1002\/14651858.CD012204.pub2"},{"issue":"1","key":"4705_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155\u201361.","journal-title":"Diabetes Care"},{"issue":"3","key":"4705_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.7326\/M22-3018","volume":"176","author":"AG Pittas","year":"2023","unstructured":"Pittas AG, Kawahara T, Jorde R, et al. Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes\u202f: A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials. Ann Intern Med. 2023;176(3):355\u201363.","journal-title":"Ann Intern Med"},{"issue":"11","key":"4705_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"4705_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"4","key":"4705_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082.","journal-title":"PLoS Med"},{"issue":"1","key":"4705_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1080","volume":"16","author":"T Papakonstantinou","year":"2020","unstructured":"Papakonstantinou T, Nikolakopoulou A, Higgins JPT, et al. CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev. 2020;16(1):e1080.","journal-title":"Campbell Syst Rev"},{"key":"4705_CR17","doi-asserted-by":"crossref","unstructured":"Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):Ed000142.","DOI":"10.1002\/14651858.ED000142"},{"key":"4705_CR18","unstructured":"8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S167-s80."},{"issue":"3","key":"4705_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3803\/EnM.2023.1690","volume":"38","author":"CRL Cardoso","year":"2023","unstructured":"Cardoso CRL, Leite NC, Salles GF. Effects of weight loss and interaction with physical activity on risks of cardiovascular outcomes in individuals with type 2 diabetes. Endocrinol Metab. 2023;38(3):305\u201314.","journal-title":"Endocrinol Metab"},{"issue":"4","key":"4705_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2337\/dc11-1918","volume":"35","author":"A Ramachandran","year":"2012","unstructured":"Ramachandran A, Riddle MC, Kabali C, et al. Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. Diabetes Care. 2012;35(4):749\u201353.","journal-title":"Diabetes Care"},{"issue":"11","key":"4705_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.42950","volume":"6","author":"J Banks","year":"2023","unstructured":"Banks J, Amspoker AB, Vaughan EM, et al. Ascertainment of Minimal Clinically Important Differences in the Diabetes Distress Scale-17: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023;6(11):e2342950.","journal-title":"JAMA Netw Open"},{"key":"4705_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4743","volume":"372","author":"JZ Goldenberg","year":"2021","unstructured":"Goldenberg JZ, Day A, Brinkworth GD, et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ. 2021;372:m4743.","journal-title":"BMJ"},{"issue":"4","key":"4705_CR23","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.amepre.2021.10.020","volume":"62","author":"KI Galaviz","year":"2022","unstructured":"Galaviz KI, Weber MB, Suvada KB, et al. Interventions for reversing prediabetes: a systematic review and meta-analysis. Am J Prev Med. 2022;62(4):614\u201325.","journal-title":"Am J Prev Med"},{"issue":"2","key":"4705_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371.","journal-title":"J Clin Epidemiol"},{"key":"4705_CR25","unstructured":"Dias S, Welton NJ, Sutton AJ, et al. NICE Decision Support Unit Technical Support Documents. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. London: National Institute for Health and Care Excellence (NICE). Copyright \u00a9 2014 National Institute for Health and Clinical Excellence, unless otherwise stated. All rights reserved.; 2014."},{"issue":"4","key":"4705_CR26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.numecd.2020.12.025","volume":"31","author":"A Rezki","year":"2021","unstructured":"Rezki A, Fysekidis M, Chiheb S, et al. Acute and long-term effects of saxagliptin on post-prandial glycemic response in obese patients with impaired glucose tolerance. Nutr Metab Cardiovasc Dis. 2021;31(4):1257\u201366.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"4705_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3132\/dvdr.2008.005","volume":"5","author":"C Snehalatha","year":"2008","unstructured":"Snehalatha C, Mary S, Joshi VV, et al. Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diab Vasc Dis Res. 2008;5(1):25\u20139.","journal-title":"Diab Vasc Dis Res"},{"issue":"2","key":"4705_CR28","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/dom.16096","volume":"27","author":"Q He","year":"2025","unstructured":"He Q, Cheng Z, Li Y, et al. A biweekly DPP-4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Diabetes Obes Metab. 2025;27(2):965\u201375.","journal-title":"Diabetes Obes Metab"},{"key":"4705_CR29","unstructured":"Cardiovascular Effects of GLP-1 Receptor Activation. 2017. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03101930."},{"key":"4705_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.154054","volume":"104","author":"R Guardado-Mendoza","year":"2020","unstructured":"Guardado-Mendoza R, Salazar-L\u00f3pez SS, \u00c1lvarez-Canales M, et al. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial. Metabolism. 2020;104:154054.","journal-title":"Metabolism"},{"issue":"8","key":"4705_CR31","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.4103\/jfmpc.jfmpc_311_21","volume":"10","author":"P Misra","year":"2021","unstructured":"Misra P, Kant S, Misra A, et al. A community based randomized controlled trial to see the effect of vitamin D supplementation on development of diabetes among women with prediabetes residing in a rural community of Northern India. Journal of Family Medicine & Primary Care. 2021;10(8):3122\u20139.","journal-title":"Journal of Family Medicine & Primary Care"},{"issue":"1","key":"4705_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/dom.12779","volume":"19","author":"P Lundkvist","year":"2017","unstructured":"Lundkvist P, Sj\u00f6str\u00f6m CD, Amini S, et al. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab. 2017;19(1):49\u201360.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"4705_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.metabol.2004.08.018","volume":"54","author":"J Biarn\u00e9s","year":"2005","unstructured":"Biarn\u00e9s J, Fern\u00e1ndez-Real JM, Fern\u00e1ndez-Casta\u00f1er M, et al. Differential regulation of insulin action and tumor necrosis factor a system activity by metformin. Metabolism-Clinical and Experimental. 2005;54(2):235\u20139.","journal-title":"Metabolism-Clinical and Experimental"},{"key":"4705_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2018.12.008","volume":"148","author":"M Niroomand","year":"2019","unstructured":"Niroomand M, Fotouhi A, Irannejad N, et al. Does high-dose vitamin D supplementation impact insulin resistance and risk of development of diabetes in patients with pre-diabetes? A double-blind randomized clinical trial. Diabetes Res Clin Pract. 2019;148:1\u20139.","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"4705_CR35","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s11606-013-2548-4","volume":"28","author":"NM Maruthur","year":"2013","unstructured":"Maruthur NM, Ma Y, Delahanty LM, et al. Early response to preventive strategies in the Diabetes Prevention Program. J Gen Intern Med. 2013;28(12):1629\u201336.","journal-title":"J Gen Intern Med"},{"key":"4705_CR36","doi-asserted-by":"crossref","unstructured":"Lau DCW, Fujioka K, Greenway F, et al. Early weight loss responders to liraglutide 3.0 Mg had greater weight loss, regression to normoglycaemia, and reduced T2D development at 3 years Vs early non-responders: SCALE obesity and prediabetes. Obesity Reviews. 2016;2):68\u20139.","DOI":"10.1016\/j.jcjd.2016.08.097"},{"issue":"3","key":"4705_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1055\/s-0029-1211981","volume":"106","author":"H Laube","year":"1998","unstructured":"Laube H, Linn T, Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes. 1998;106(3):231\u20133.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"11","key":"4705_CR38","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/diacare.19.11.1190","volume":"19","author":"JL Chiasson","year":"1996","unstructured":"Chiasson JL, Josse RG, Leiter LA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care. 1996;19(11):1190\u20133.","journal-title":"Diabetes Care"},{"issue":"8","key":"4705_CR39","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1055\/a-0664-7583","volume":"128","author":"AM Ram\u00edrez-Rodr\u00edguez","year":"2020","unstructured":"Ram\u00edrez-Rodr\u00edguez AM, Gonz\u00e1lez-Ortiz M, Mart\u00ednez-Abundis E. Effect of Dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Exp Clin Endocrinol Diabetes. 2020;128(8):506\u201311.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"4705_CR40","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.1038\/s41598-021-88108-8","volume":"11","author":"MFL Alvarez-Canales","year":"2021","unstructured":"Alvarez-Canales MFL, Salazar-L\u00f3pez SS, Farf\u00e1n-V\u00e1zquez D, et al. Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle. Sci Rep. 2021;11(1):8750.","journal-title":"Sci Rep"},{"issue":"8","key":"4705_CR41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1089\/dia.2017.0020","volume":"19","author":"T Gonz\u00e1lez-Heredia","year":"2017","unstructured":"Gonz\u00e1lez-Heredia T, Hern\u00e1ndez-Corona DM, Gonz\u00e1lez-Ortiz M, et al. Effect of Linagliptin Versus Metformin on glycemic variability in patients with impaired glucose tolerance. Diabetes Technol Ther. 2017;19(8):471\u20135.","journal-title":"Diabetes Technol Ther"},{"key":"4705_CR42","doi-asserted-by":"crossref","unstructured":"Liping SUN, Yuan Y, Yongmei LI, et al. Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: a double\u2011blind, randomized controlled clinical trial. Experimental and therapeutic medicine. 2023;25(6).","DOI":"10.3892\/etm.2023.11948"},{"issue":"3","key":"4705_CR43","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/jcsm.13445","volume":"15","author":"A Pandey","year":"2024","unstructured":"Pandey A, Patel KV, Segar MW, et al. Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial. J Cachexia Sarcopenia Muscle. 2024;15(3):1072\u201383.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"4705_CR44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.dsx.2017.11.003","volume":"12","author":"N Bulatova","year":"2018","unstructured":"Bulatova N, Kasabri V, Qotineh A, et al. Effect of metformin combined with lifestyle modification versus lifestyle modification alone on proinflammatory-oxidative status in drug-na\u00efve pre-diabetic and diabetic patients: A randomized controlled study. Diabetes Metab Syndr. 2018;12(3):257\u201367.","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"4705_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2337\/dc06-0210","volume":"30","author":"B Richelsen","year":"2007","unstructured":"Richelsen B, Tonstad S, R\u00f6ssner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care. 2007;30(1):27\u201332.","journal-title":"Diabetes Care"},{"issue":"3","key":"4705_CR46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1753-0407.12833","volume":"11","author":"P Portillo-Sanchez","year":"2019","unstructured":"Portillo-Sanchez P, Bril F, Lomonaco R, et al. Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial. J Diabetes. 2019;11(3):223\u201331.","journal-title":"J Diabetes"},{"issue":"3","key":"4705_CR47","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1530\/eje.1.02100","volume":"154","author":"SG Kim","year":"2006","unstructured":"Kim SG, Ryu OH, Kim HY, et al. Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur J Endocrinol. 2006;154(3):433\u201340.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"4705_CR48","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1002\/oby.23842","volume":"31","author":"L Wilkinson","year":"2023","unstructured":"Wilkinson L, Holst-Hansen T, Laursen PN, et al. Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity. Obesity. 2023;31(9):2249\u201359.","journal-title":"Obesity"},{"issue":"11","key":"4705_CR49","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1007\/s00125-018-4716-x","volume":"61","author":"KJ Nahon","year":"2018","unstructured":"Nahon KJ, Doornink F, Straat ME, et al. Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial. Diabetologia. 2018;61(11):2386\u201397.","journal-title":"Diabetologia"},{"issue":"3","key":"4705_CR50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.4103\/2230-8210.152783","volume":"19","author":"MS Kuchay","year":"2015","unstructured":"Kuchay MS, Laway BA, Bashir MI, et al. Effect of Vitamin D supplementation on glycemic parameters and progression of prediabetes to diabetes: a 1-year, open-label randomized study. Indian J Endocrinol Metab. 2015;19(3):387\u201392.","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"4705_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/dom.12794","volume":"19","author":"TS Moreira-Lucas","year":"2017","unstructured":"Moreira-Lucas TS, Duncan AM, Rabasa-Lhoret R, et al. Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): A double-blind, randomized, placebo-controlled clinical trial. Diabetes Obes Metab. 2017;19(1):133\u201341.","journal-title":"Diabetes Obes Metab"},{"key":"4705_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s40795-019-0311-x","volume":"5","author":"M Al Thani","year":"2019","unstructured":"Al Thani M, Sadoun E, Sofroniou A, et al. The effect of vitamin D supplementation on the glycemic control of pre-diabetic Qatari patients in a randomized control trial. BMC Nutr. 2019;5:46.","journal-title":"BMC Nutr"},{"key":"4705_CR53","doi-asserted-by":"crossref","unstructured":"Zarrin R, Ayremlou P, Ghassemi F. The effect of vitamin D supplementation on the glycemic status and the percentage of body fat mass in adults with prediabetes: A randomized clinical trial. Iranian Red Crescent Medical Journal. 2017;19(3) (no pagination).","DOI":"10.5812\/ircmj.41718"},{"issue":"5","key":"4705_CR54","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/ajcn\/nqz171","volume":"110","author":"HJ Wallace","year":"2019","unstructured":"Wallace HJ, Holmes L, Ennis CN, et al. Effect of vitamin D3 supplementation on insulin resistance and \u03b2-cell function in prediabetes: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2019;110(5):1138\u201347.","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"4705_CR55","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/MBP.0000000000000479","volume":"25","author":"C D\u00edaz-Cruz","year":"2020","unstructured":"D\u00edaz-Cruz C, Gonz\u00e1lez-Ortiz M, Rosales-Rivera LY, et al. Effects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial. Blood Press Monit. 2020;25(6):346\u201350.","journal-title":"Blood Press Monit"},{"key":"4705_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/nu10030383","author":"HA Alfawaz","year":"2018","unstructured":"Alfawaz HA, Wani K, Alnaami AM, et al. Effects of different dietary and lifestyle modification therapies on metabolic syndrome in prediabetic Arab patients: a 12-month longitudinal study. Nutrients. 2018. https:\/\/doi.org\/10.3390\/nu10030383.","journal-title":"Nutrients"},{"key":"4705_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.diabres.2017.05.012","volume":"130","author":"Z Wang","year":"2017","unstructured":"Wang Z, Xu D, Huang L, et al. Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes. Diabetes Res Clin Pract. 2017;130:77\u201385.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"4705_CR58","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2337\/dc07-1616","volume":"31","author":"J Rosenstock","year":"2008","unstructured":"Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31(1):30\u20135.","journal-title":"Diabetes Care"},{"issue":"4","key":"4705_CR59","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/dom.12625","volume":"18","author":"NG Forouhi","year":"2016","unstructured":"Forouhi NG, Menon RK, Sharp SJ, et al. <article-title update=\"added\"> Effects of vitamin <scp> D 2<\/scp> or <scp> D 3<\/scp> supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double\u2010blind placebo\u2010controlled trial. Diabetes Obes Metab. 2016;18(4):392\u2013400.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"4705_CR60","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan BM, Bruun JM, Capehorn M, et al. Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;12(9):631\u201342.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"4705_CR61","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1152\/japplphysiol.00790.2016","volume":"123","author":"R Viskochil","year":"2017","unstructured":"Viskochil R, Malin SK, Blankenship JM, et al. Exercise training and metformin, but not exercise training alone, decreases insulin production and increases insulin clearance in adults with prediabetes. J Appl Physiol. 2017;123(1):243\u20138.","journal-title":"J Appl Physiol"},{"key":"4705_CR62","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/672653","volume":"2015","author":"TP Tuomainen","year":"2015","unstructured":"Tuomainen TP, Virtanen JK, Voutilainen S, et al. Glucose metabolism effects of vitamin D in prediabetes: the VitDmet randomized placebo-controlled supplementation study. J Diabetes Res. 2015;2015:672653.","journal-title":"J Diabetes Res"},{"issue":"1","key":"4705_CR63","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2337\/dc11-0925","volume":"35","author":"SK Malin","year":"2012","unstructured":"Malin SK, Gerber R, Chipkin SR, et al. Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. Diabetes Care. 2012;35(1):131\u20136.","journal-title":"Diabetes Care"},{"issue":"7","key":"4705_CR64","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1046\/j.1464-5491.2001.00539.x","volume":"18","author":"M Lehtovirta","year":"2001","unstructured":"Lehtovirta M, Fors\u00e9n B, Gullstr\u00f6m M, et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med. 2001;18(7):578\u201383.","journal-title":"Diabet Med"},{"issue":"8","key":"4705_CR65","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.2337\/dc14-0218","volume":"37","author":"ST Sollid","year":"2014","unstructured":"Sollid ST, Hutchinson MY, Fuskev\u00e5g OM, et al. No effect of high-dose vitamin D supplementation on glycemic status or cardiovascular risk factors in subjects with prediabetes. Diabetes Care. 2014;37(8):2123\u201331.","journal-title":"Diabetes Care"},{"issue":"3","key":"4705_CR66","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00125-013-3134-3","volume":"57","author":"SH Kim","year":"2014","unstructured":"Kim SH, Liu A, Ariel D, et al. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study. Diabetologia. 2014;57(3):455\u201362.","journal-title":"Diabetologia"},{"issue":"12","key":"4705_CR67","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","volume":"364","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104\u201315.","journal-title":"N Engl J Med"},{"issue":"2","key":"4705_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1055\/s-2003-39236","volume":"111","author":"F Guerrero-Romero","year":"2003","unstructured":"Guerrero-Romero F, Rodr\u00edguez-Mor\u00e1n M. Pioglitazone increases serum magnesium levels in glucose-intolerant subjects. A randomized, controlled trial. Exp Clin Endocrinol Diabetes. 2003;111(2):91\u20136.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"4705_CR69","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12020-023-03384-w","volume":"81","author":"L Bruhn","year":"2023","unstructured":"Bruhn L, Vistisen D, Amadid H, et al. Predicting the HbA1c level following glucose-lowering interventions in individuals with HbA1c-defined prediabetes: a post-hoc analysis from the randomized controlled PRE-D trial. Endocrine. 2023;81(1):67\u201376.","journal-title":"Endocrine"},{"issue":"7","key":"4705_CR70","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1742-1241.2002.tb11307.x","volume":"56","author":"I Broom","year":"2002","unstructured":"Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. Int J Clin Pract. 2002;56(7):494\u20139.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"4705_CR71","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/10815589231225183","volume":"72","author":"LA Abushamat","year":"2024","unstructured":"Abushamat LA, Schauer IE, Low Wang CC, et al. Rosiglitazone improves insulin resistance but does not improve exercise capacity in individuals with impaired glucose tolerance: a randomized clinical study. J Investig Med. 2024;72(3):294\u2013304.","journal-title":"J Investig Med"},{"issue":"4","key":"4705_CR72","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.metabol.2005.10.004","volume":"55","author":"YJ Hung","year":"2006","unstructured":"Hung YJ, Lin SH, Pei D, et al. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. Metabolism. 2006;55(4):439\u201344.","journal-title":"Metabolism"},{"issue":"5","key":"4705_CR73","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1464-5491.2004.01155.x","volume":"21","author":"SM Bennett","year":"2004","unstructured":"Bennett SM, Agrawal A, Elasha H, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med. 2004;21(5):415\u201322.","journal-title":"Diabet Med"},{"key":"4705_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2022.111738","volume":"556","author":"AKN Pedersen","year":"2022","unstructured":"Pedersen AKN, Hage C, Jessen N, et al. Sitagliptin reduces FAP-activity and increases intact FGF21 levels in patients with newly detected glucose abnormalities. Mol Cell Endocrinol. 2022;556:111738.","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"4705_CR75","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1111\/dom.15269","volume":"25","author":"ER Hankosky","year":"2023","unstructured":"Hankosky ER, Wang H, Neff LM, et al. Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: post hoc analysis of the SURMOUNT-1 trial. Diabetes Obes Metab. 2023;25(12):3748\u201356.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"4705_CR76","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.2337\/dc06-0061","volume":"29","author":"MS Kirkman","year":"2006","unstructured":"Kirkman MS, Shankar RR, Shankar S, et al. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the early diabetes intervention program. Diabetes Care. 2006;29(9):2095\u2013101.","journal-title":"Diabetes Care"},{"issue":"3","key":"4705_CR77","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1172\/JCI119562","volume":"100","author":"MK Cavaghan","year":"1997","unstructured":"Cavaghan MK, Ehrmann DA, Byrne MM, et al. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997;100(3):530\u20137.","journal-title":"J Clin Invest"},{"key":"4705_CR78","unstructured":"Papamargaritis D, Garvey WT, Batterham RL, et al. Two-year Effect of Semaglutide 2.4 mg vs Placebo in Adults with Overweight or Obesity: STEP-5. International journal of obesity. 2023;47:24\u20105."},{"issue":"4","key":"4705_CR79","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1210\/jc.2015-4013","volume":"101","author":"R Jorde","year":"2016","unstructured":"Jorde R, Sollid ST, Svartberg J, et al. Vitamin D 20,000 IU per Week for Five Years Does Not Prevent Progression From Prediabetes to Diabetes. J Clin Endocrinol Metab. 2016;101(4):1647\u201355.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4705_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56904-y","volume":"10","author":"SP Bhatt","year":"2020","unstructured":"Bhatt SP, Misra A, Pandey RM, et al. Vitamin D supplementation in overweight\/obese Asian Indian women with prediabetes reduces glycemic measures and truncal subcutaneous fat: a 78 weeks randomized placebo-controlled trial (PREVENT-WIN Trial). Sci Rep. 2020;10(1):220.","journal-title":"Sci Rep"},{"key":"4705_CR81","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-025-01552-2","author":"S Oh","year":"2025","unstructured":"Oh S, Park SE, Kim E. Evaluation of bone health and fracture risk in type 2 diabetes: a network meta-analysis of anti-diabetic treatments versus placebo. Arch Pharm Res. 2025. https:\/\/doi.org\/10.1007\/s12272-025-01552-2.","journal-title":"Arch Pharm Res"},{"key":"4705_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156276","volume":"169","author":"H Huang","year":"2025","unstructured":"Huang H, Ruan H, Lu X, et al. Comprehensive assessment of the causal effects and metabolite mediators of glucose-lowering drug targets on cardio-renal-liver-metabolic health. Metabolism. 2025;169:156276.","journal-title":"Metabolism"},{"issue":"7","key":"4705_CR83","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463\u201374.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"4705_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102697","volume":"17","author":"D Dutta","year":"2023","unstructured":"Dutta D, Bhattacharya S, Kumar M, et al. Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis. Diabetes Metab Syndr. 2023;17(1):102697.","journal-title":"Diabetes Metab Syndr"},{"issue":"6","key":"4705_CR85","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2013403.","journal-title":"N Engl J Med"},{"issue":"10","key":"4705_CR86","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40265-015-0416-8","volume":"75","author":"U Hostalek","year":"2015","unstructured":"Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071\u201394.","journal-title":"Drugs"},{"key":"4705_CR87","doi-asserted-by":"crossref","unstructured":"van Ruiten CC, van der Aart-van der Beek AB, RG IJ, et al. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial. Diabetes Obes Metab. 2021;23(8):1851\u20138.","DOI":"10.1111\/dom.14410"},{"issue":"10166","key":"4705_CR88","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"key":"4705_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101654","volume":"53","author":"K McCarthy","year":"2022","unstructured":"McCarthy K, Laird E, O\u2019Halloran AM, et al. Association between vitamin D deficiency and the risk of prevalent type 2 diabetes and incident prediabetes: a prospective cohort study using data from The Irish Longitudinal Study on Ageing (TILDA). EClinicalMedicine. 2022;53:101654.","journal-title":"EClinicalMedicine"},{"key":"4705_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/nu14102049","author":"I Bennour","year":"2022","unstructured":"Bennour I, Haroun N, Sicard F, et al. Vitamin D and obesity\/adiposity-a brief overview of recent studies. Nutrients. 2022. https:\/\/doi.org\/10.3390\/nu14102049.","journal-title":"Nutrients"},{"issue":"4","key":"4705_CR91","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/obr.12239","volume":"16","author":"M Pereira-Santos","year":"2015","unstructured":"Pereira-Santos M, Costa PR, Assis AM, et al. Obesity and vitamin D deficiency: a systematic review and meta-analysis. Obes Rev. 2015;16(4):341\u20139.","journal-title":"Obes Rev"},{"issue":"12","key":"4705_CR92","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1001\/jamainternmed.2017.6040","volume":"177","author":"JS Haw","year":"2017","unstructured":"Haw JS, Galaviz KI, Straus AN, et al. Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2017;177(12):1808\u201317.","journal-title":"JAMA Intern Med"},{"issue":"9702","key":"4705_CR93","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","volume":"374","author":"WC Knowler","year":"2009","unstructured":"Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677\u201386.","journal-title":"Lancet"},{"issue":"3","key":"4705_CR94","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2337\/dc07-9920","volume":"30","author":"DM Nathan","year":"2007","unstructured":"Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30(3):753\u20139.","journal-title":"Diabetes Care"},{"issue":"7","key":"4705_CR95","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1210\/jc.2018-02610","volume":"104","author":"TV Fiorentino","year":"2019","unstructured":"Fiorentino TV, Pedace E, Succurro E, et al. Individuals with prediabetes display different age-related pathophysiological characteristics. J Clin Endocrinol Metab. 2019;104(7):2911\u201324.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04705-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04705-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04705-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:05:35Z","timestamp":1774523135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04705-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4705"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04705-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study did not involve clinical trials or animal experiments, and had no access to individual participants or their personal information, obtaining consent for publication was not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Current study did not involve individual participants directly, so there was no access to participants or their personal information. Therefore, obtaining consent for publication was not applicable.There are no patient representatives or members of the public attend the study\u2019s planning, design, conduct, or reporting.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}